KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Current Deferred Revenue: 2017-2024

Historic Current Deferred Revenue for Elanco Animal Health (ELAN) over the last 8 years, with Dec 2024 value amounting to $332.0 million.

  • Elanco Animal Health's Current Deferred Revenue rose 12.91% to $376.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.0 million, marking a year-over-year increase of 12.91%. This contributed to the annual value of $332.0 million for FY2024, which is 9.54% down from last year.
  • As of FY2024, Elanco Animal Health's Current Deferred Revenue stood at $332.0 million, which was down 9.54% from $367.0 million recorded in FY2023.
  • Elanco Animal Health's Current Deferred Revenue's 5-year high stood at $367.0 million during FY2023, with a 5-year trough of $297.0 million in FY2020.
  • Moreover, its 3-year median value for Current Deferred Revenue was $332.0 million (2024), whereas its average is $341.0 million.
  • In the last 5 years, Elanco Animal Health's Current Deferred Revenue skyrocketed by 40.76% in 2020 and then decreased by 9.54% in 2024.
  • Elanco Animal Health's Current Deferred Revenue (MRY) stood at $297.0 million in 2020, then grew by 7.41% to $319.0 million in 2021, then grew by 1.57% to $324.0 million in 2022, then rose by 13.27% to $367.0 million in 2023, then decreased by 9.54% to $332.0 million in 2024.
  • Its Current Deferred Revenue stands at $332.0 million for FY2024, versus $367.0 million for FY2023 and $324.0 million for FY2022.